Business
Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)
LOUISVILLE, Ky., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron Pharmaceuticals for Lynozyfic™ (linvoseltamab-gcpt), which has been has granted accelerated approval by the Food and Drug Administration to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulato
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"image","alt":"Onco360 Oncology Pharmacy","displaySize":"","headline":null,"caption":"Onco360 Oncology Pharmacy","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/3a05e80b733010fa06ba372296fc1e2b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BZM0vMjfPRpb6XJ.Da6dUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3a05e80b733010fa06ba372296fc1e2b","width":300,"height":100}},"lazy":false},{"type":"text","content":"LOUISVILLE, Ky., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron Pharmaceuticals for Lynozyfic™ (linvoseltamab-gcpt), which has been has granted accelerated approval by the Food and Drug Administration to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 Lynozyfic was granted accelerated approval based on response rate and durability of response in the LINKER-MM1 trial.2","length":672,"tagName":"p"},{"type":"text","content":"“Onco360 is grateful for the opportunity to partner with the Regeneron team and become a specialty pharmacy provider for Lynozyfic,” said Benito Fernandez, Chief Commercial Officer. “We are proud to add this targeted therapy to our portfolio to treat patients with relapsed/refractory multiple myeloma.”","length":303,"tagName":"p"},{"type":"text","content":"Linvoseltamab is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells.1 Linvoseltamab is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. Lynozyfic is available only through the Lynozyfic Risk Evaluation and Mitigation Strategy (REMS) due to the risk of cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity sy...